Is Ozempic and Wegovy exactly the same medicine?

Where Ozempic and Wegovy actually overlap, and where they part ways

The confusion is understandable. Both drugs were developed by Novo Nordisk, both inject once a week under the skin, and both work by activating GLP-1 receptors, slowing gastric emptying, reducing appetite and helping regulate blood sugar. If you looked at the active molecule under a microscope, you would see the same structure. That is where the overlap ends.

Their UK licences are separate and specific. Ozempic is approved by the MHRA for adults with type 2 diabetes to improve blood-sugar control. Wegovy's licence covers weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure or pre-diabetes. A prescriber writing for weight loss must prescribe Wegovy, not Ozempic. The detailed comparison of these two licences sets out exactly how the regulatory boundary is drawn.

Dose is also a significant difference. Wegovy was designed from the outset to reach a 2.4 mg weekly maintenance dose, and since April 2026 a dedicated 7.2 mg pen has been approved by the MHRA for adults with obesity. Ozempic's doses top out at 1 mg (and 2 mg in some presentations) because higher exposures were not needed to hit its glycaemic targets. So even if a pharmacist placed both pens side by side, they would not be interchangeable.

Why this matters if you are thinking about semaglutide for weight loss

People sometimes arrive at online pharmacies asking specifically for Ozempic after reading about it in the press. The licensing reality is that a regulated UK prescriber cannot (and should not) prescribe Ozempic for weight loss as a first-line choice when Wegovy exists precisely for that indication. Prescribing outside a medicine's licence is not automatically illegal, but it carries additional clinical and legal responsibility that most responsible prescribers will not take on without compelling clinical reason.

There is also a supply-and-cost dimension. During the semaglutide shortage period, some clinics moved patients onto Ozempic off-label. That is now a historical oddity rather than current practice. If you are researching the options for obtaining Wegovy through a legitimate route, you want a service that prescribes within licences as a matter of principle. For full background on how the mechanism actually produces weight loss, this page covers what Wegovy does in the body in plain language.

Worth noting: if you have been offered a supply of Ozempic for weight loss at an unusually low price through social media, that is a genuine red flag. The MHRA has seized large volumes of illegally traded weight-loss pens and warns that fake products have caused serious harm. Report anything suspicious through the Yellow Card scheme.

What IS licensed for weight loss in the UK, and how to access it properly

The two medicines approved for weight management in the UK are Wegovy (semaglutide) and Mounjaro (tirzepatide). Wegovy is a GLP-1 receptor agonist; Mounjaro activates both GLP-1 and GIP receptors, making it the only dual-agonist option currently available here. Both require a prescription following clinical assessment, and both have solid clinical trial evidence behind them at their licensed doses. A useful overview of the broader weight-loss treatment landscape covers how they compare and who tends to be suitable for each.

If you are wondering whether Ozempic and Wegovy are exactly the same because you have been prescribed Ozempic and want to switch, that is a conversation for your prescriber rather than something to self-manage. Titration schedules and clinical rationale need to be reviewed before any change. Keep whichever pen you are using in the fridge (between 2 and 8°C, away from the freezer compartment) and consult the Patient Information Leaflet for the exact room-temperature window if you need to travel. Storage specifics for Wegovy are covered in detail on this page about temperature requirements.

The right place to start, if weight management is the goal, is a clinical consultation where a prescriber reviews your health history and decides which licensed medicine, if any, is appropriate for you. The mechanism behind Wegovy's effects is also worth reading if you want to understand what you would be starting before speaking to a clinician. As the NHS semaglutide guidance makes clear, semaglutide in any form is a prescription-only medicine, and the licensed indication determines what a prescriber may appropriately offer.